Table 1.

Overview of the patients in the lipidomic cohort

	Normal control	Healthy obese	NAFL	Early NASH	NASH
Age	70.5 (63.5–74)	43.5 (35.3–48.0)	43 (34–52.5)	44 (34–51)	46.5 (35–51.2)
BMI	24.6 (21.7–26.3)	48.9 (44.3–52.5)	47.8 (42.2–52.7)	50.4 (44.2–54.1)	55.2 (49.6–59.2)
Sex % male	50	6.5	34.6	37.7	21.8
Fat (area in %)	≤5	≤5	>5	>5	>5
NAS score	0 (0–0)	0 (0–0)	1 (1–2)	3 (2–3)	5 (5–6)
NAS fat	0 (0–0)	0 (0–0)	1 (1–2)	2 (1–2)	3 (3–3)
NAS ballooning	0 (0–0)	0 (0–0)	0 (0–0)	0 (0–0)	1 (1–1)
NAS inflammation	0 (0–0)	0 (0–0)	0 (0–0)	1 (1–1)	1 (1–1.25)
Fibrosis	0 (0–0)	0 (0–0)	0 (0–1)	1 (0–1)	1 (1–1)
NAFLD without fibrosis (CC/CT/TT)	NA	NA	30/49/13	9/10/6	1/4/2
NAFLD with fibrosis (CC/CT/TT)	NA	NA	11/22/10	13/7/4	7/13/3
Total MBOAT7 rs641738 (CC/CT/TT) (n=280)	10/14/6	13/17/6	41/71/23	22/17/10	8/17/5

Patients are grouped by histology using the NAS score as the main classification criteria. Values are given as median with IQR in parentheses. Additional information is provided in online supplementary tables 8 and 9.

BMI, body mass index; MBOAT7, membrane-bound O-acyltransferase domain containing 7; NA, not applicable; NAFLD, non-alcoholic fatty liver disease; NAS, NAFLD Activity Score; NASH, non-alcoholic steatohepatitis.